Form 8-K - Current report:
SEC Accession No. 0001140361-21-031134
Filing Date
2021-09-14
Accepted
2021-09-14 07:00:42
Documents
15
Period of Report
2021-09-14
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K brhc10028918_8k.htm   iXBRL 8-K 28125
2 EXHIBIT 99.1 brhc10028918_ex99-1.htm EX-99.1 14766
6 image00002.jpg GRAPHIC 5905
7 image00003.jpg GRAPHIC 2561
  Complete submission text file 0001140361-21-031134.txt   195123

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA btx-20210914.xsd EX-101.SCH 3929
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE btx-20210914_lab.xml EX-101.LAB 22544
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE btx-20210914_pre.xml EX-101.PRE 16047
8 EXTRACTED XBRL INSTANCE DOCUMENT brhc10028918_8k_htm.xml XML 4220
Mailing Address 140 58TH STREET, BUILDING A SUITE 2100 BROOKLYN NY 11220
Business Address 140 58TH STREET, BUILDING A SUITE 2100 BROOKLYN NY 11220 (212) 582-1199
Brooklyn ImmunoTherapeutics, Inc. (Filer) CIK: 0000748592 (see all company filings)

EIN.: 311103425 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-11460 | Film No.: 211251209
SIC: 2834 Pharmaceutical Preparations